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Hyaluronic Acid Derivatives for 
Targeted Cancer Therapy
Nilkamal Pramanik and Sameer Kumar Jagirdar
Abstract
Targeted therapeutics are considered next generation cancer therapy because 
they overcome many limitations of traditional chemotherapy. Cancerous cells may 
be targeted by various hyaluronic acid modified nanovehicles that kill these cells. 
Particularly, hyaluronic acid and its derivatives bind with high affinity to cell sur-
face protein, CD44 enriched tumor cells. Moreover, these molecules have the added 
advantage of being biocompatible and biodegradable, and may be conjugated with 
a variety of drugs and drug carriers for developing various formulations as anti-
cancer therapies such as nanogels, self-assembled and metallic nanoparticulates. In 
this chapter, we have covered various aspects of hyaluronic acid-modified delivery 
systems including strategies for synthesis, characterization, and biocompatibility. 
Next, the use of hyaluronic acid-modified systems as anti-cancer therapies is 
discussed. Finally, the delivery of small molecules, and other pharmaceutical agents 
are also elaborated in this chapter.
Keywords: Hyaluronic Acid, Nano-particulates, Immunogenicity, Biodegradation, 
Tumor Targeted delivery
1. Introduction
Nanoparticles have gained increased attention in the context of cancer therapy; 
however, the major challenge of targeting particles specifically to cancerous cells 
remains. Targeted delivery systems comprising cell-targeting ligands such as 
antibodies, peptides, folic acid, and various biomolecules have been developed to 
ensure tumor-specific delivery. One such targeting ligand is hyaluronic acid (HA).
HA, a glycosaminoglycan (GAG), is a natural polysaccharide present in the 
extracellular matrix of various soft connective tissues such as the vitreous humor, 
dermis of the skin, hyaline cartilage, and synovial fluid of the body. It is water-
soluble, viscoelastic, biodegradable, biocompatible, and non-immunogenic [1–4]. HA 
is a polyanionic mucopolysaccharide consisting of β-1,3 and β-1,4 glycosidic bonds 
between repeating units of D-glucuronic acid and N-acetyl-D-glucosamine [5].
As an intrinsic part of the ECM, HA participates in different biological 
functions of the cell, including signal transduction, vascularization, cell 
migration, and tissue remodeling as schematically represented in Figure 1. 
Additionally, the presence of modifiable hydrophilic functional groups—
hydroxyl, carboxyl, and N-acetyl increases its potential as an adaptable system 
for the delivery of proteins, nucleic acids, and anti-cancer agents by grafting or 
modification with different nanoparticles. Based on cellular interaction stud-
ies, HA has emerged as a tumor-targeting agent in cancer therapy. It exhibits a 
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high binding affinity towards the CD44 cluster [6], which is over-expressed in 
numerous malignant cancer cells [7–9].
Considering its hierarchical structure and potential as a targeting agent, HA can 
be modified using small biomolecules [10], nanotubes [11], or different types of 
metal and non-metal nanoparticles [12] in various formulations. HA modified par-
ticles are effectively ingested by cells, and HA is enzymatically degraded intracellu-
larly [13], resulting in the delivery of only the particles and their cargo inside the cell.
This chapter covers various aspects of HA-modified delivery systems, includ-
ing strategies for synthesis, characterization, and biocompatibility. Furthermore, 
the characteristics of different delivery systems such as nanogel, micelle, 
liposome, and metallic or non-metallic nano-particulates are discussed. The 
mechanism underlying the delivery of small molecules, nucleic acids, and other 
pharmaceutical agents (in vitro, in vivo, or clinical applicability) are also pre-
sented in this chapter.
2. Hyaluronic acid–a primer
HA was discovered in 1934 when scientists Karl Meyer and John Palmer isolated 
a new kind of polysaccharide from bovine vitreous humor, which was later termed 
as hyaluronan [14]. Hyaluronic acid is a polysaccharide composed of repeating units 
of β-1,3-N-acetyl-D-glucosamine and β-1,4-D-glucuronic acid linked by β-1,3 and 
β-1,4 glycosidic bonds. It is a component of the extracellular matrix and mediates 
various cellular functions. HA is a ligand for the cell surface receptor CD44. CD44 
Figure 1. 
Schematic representation of physico-chemical properties and functions of hyaluronic acid (HA) in the native 
tissue environment.
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is a transmembrane protein that is typically expressed by a number of cells, but 
is over-expressed in different types of metastatic tumor cells, including those of 
brain, breast, prostate, colon, bladder, and head and neck cancers [7–9, 15–17]. It 
has a significant role in cell proliferation, migration, metastasis, and cell–cell and 
cell-matrix signal transduction [18].
2.1 Synthesis
Hyaluronic acid is usually obtained from different biological sources. The 
microbial synthesis pathway is preferred as it is cost-effective and an environmen-
tally benign process. The gram-positive bacterium, Streptococcus zooepidemicus 
is used for large-scale production of HA via a fermentative pathway as shown in 
Figure 2(A) [19]. The biosynthetic pathway of HA is as follows: initially, glucose-
6-phosphate is converted to uridine diphosphate glucose (UDP-glucose) in the 
presence of α-phosphoglucomutase and UDP-glucose dehydrogenase followed by 
UDP-glucose dehydrogenase assisted oxidation into UDP-glucuronic acid. Next, 
an amide group is transferred from glutamine-fructose-6-phosphate to fructose-
6-phosphate, followed by rearrangement of the phosphate leading to the forma-
tion of glucosamine-1-phosphate. Subsequently, acetylation and conjugation of 
UTP to glucosamine-1-phosphate generates the second precursor of HA. In the 
final step, hyaluronan synthase polymerizes the two precursors to produce HA, 
which is presented as an extracellular capsule as confirmed by electron micros-
copy (see Figure 2(B)) [20]. However, the pathogenicity of the bacterium limits 
its use for mass production of HA and therefore, several recombinant strains 
such as Agrobacterium sp. ATCC 31749 and recombinant Escherichia coli have been 
adapted as an alternative source of HA production [21, 22].
Figure 2. 
(A) Hyaluronic acid biosynthetic pathway in S. zooepidemicus. Glucose is first converted to glucose-6-phosphate 
by hexokinase which then enters one of two distinct pathways to form UDP-glucuronic acid (pgm, hasC 
and hasB) or UDP-N-acetylglucosamine (hasE, glmS, glmM and hasD). These precursors are subsequently 
bound together via the action of hyaluronic acid synthase or HAVE (encoded by hasA in S. zooepidemicus) 
to form hyaluronic acid. [Ref. [19], reproduced with permission from publishing authority]. (B) Electron 
micrograph section of Streptococcus equi subsp. Zooepidemicus (S. zooepidemicus) cells obtained from the 
late exponential phase of an aerated bioreactor culture. Thin sections were stained with uranyl acetate and lead 
citrate and examined with a Jeol JEM-1010 transmission electron microscope at an accelerating voltage of 80 kV. 
Bar 1 μm. [Ref. [20], reproduced with permission from publishing authority].
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2.2 Properties and uses
As mentioned previously, HA is a polymer. The physiochemical properties 
such as rheology and viscoelasticity of the polymer depend on the length of HA. 
Previous studies have demonstrated that higher molecular weight HA has bet-
ter wound healing properties and is more effective for orthopedic treatment 
whereas low molecular weight HA has a prominent role in angiogenesis and is 
an effective immuno-stimulant [23]. A variety of HA oligosaccharides have been 
synthesized chemically, ranging from disaccharides to hexasaccharides to improve 
biomedical availability and use. Lu et al. synthesized HA decasaccharides using 
a chemoselective glycosylation pathway [24]. Commercially available D-glucose 
and D-glucosamine hydrochloride are chemically connected in the presence of an 
activator to generate various HA-derivatives [25].
3. Applications in cancer therapy
On the basis of their physiochemical properties, different HA-based nano-
formulations have been investigated for their therapeutic application in tumor-
therapy. HA conjugated drugs, polymers, and lipids may self-assemble in aqueous 
solvents, and this property has been used to synthesize a number of self-assembled 
nano-particulates that are either made of the drug or contain the drug.
3.1 Drug-HA conjugates
Direct conjugation of drug molecules with HA results in the development of 
systems that are not only capable of targeting but improve solubility as well as blood 
circulation times of the drug itself. Some of the methods to synthesize drug-HA 
nanoparticles are summarized in Figure 3, and below, we discuss a few examples of 
the use of HA in developing new anti-cancer therapeutics.
The first example, presented in Figure 3(A), involves the conjugation of HA 
with succinic anhydride derived paclitaxel (2-succPTX, a tubulin inhibitor) 
using glutathione (GSH) sensitive cystamine (or non-sensitive adipic dihy-
drazide) as a cross-linker. The resultant self-assembled nanoparticles formed 
were analyzed using 1H nuclear magnetic resonance (NMR), Fourier-transform 
infrared spectroscopy (FTIR), and UV–visible spectroscopy. Transmission 
electron microscopy (TEM) and atomic force microscopy (AFM) analysis dem-
onstrated the presence of spherical shaped nanoparticles of diameter 150 nm. 
The nanoparticles accurately targeted cancer cells with significant anti-tumor 
efficacy both in vitro and in vivo as compared to free PTX [26]. Along similar 
lines, another HA-PTX nanovehicle showed excellent results in reducing tumor 
size with the increase of survival rate in an in vivo mouse xenograft model bear-
ing ovarian cancer cells [27]. A recent development in this area was to improve 
the loading of PTX in these self-assembled nanoparticles through the use of 
dimethylsulfoxide (DMSO) and polyethylene glycol (PEG) in the organic phase. 
This nano-system was suggested to have a 10–20% increase in PTX loading, and 
as a result, had significant anti-tumor activity against the RT-4 and RT-112/84 
bladder carcinoma cell-lines [28].
The second example is the synthesis of a HA-doxorubicin (DOX) based self-
assembled pro-drug that formed spherical core-shell nanostructures (Figure 3(B)) 
of 180–200 nm diameter. It displayed good biocompatibility and pH-responsive 
controlled Dox release in a cervical cancer model and exhibited excellent tumor 
inhibitory effects [29]. An ion-pairing based Dox-HA nano-assembled structure 
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with a liposomal delivery system displayed sustained intracellular release of Dox in 
CD44+ cancer cells with enhanced therapeutic efficacy in a mouse model [30].
The third and final example is the conjugation of HA with cisplatin. Cisplatin is 
an anti-cancer drug that causes adverse side-effects. Increasing cancer cell-specific 
intracellular delivery of cisplatin may reduce side effects, which might be possible by 
conjugating HA onto the drug. Ling et al. have demonstrated the synthesis of HA con-
jugated cisplatin using N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochlo-
ride. The synthesized pro-drug was verified using 1HNMR, 13C NMR, FT-NIR, AFM, 
and DSC analysis. The prepared pro-drug was spherical (Figure 3(C)) and showed 
CD44 mediated endocytosis with negligible stimulation to blood vessels. Systemic 
toxicity studies indicated that the drug was safe and actively delivered cisplatin to kill 
tumor cells with reduced adverse effect on healthy cells [31].
3.2 Drug loaded HA based nanoparticles
HA may also be conjugated with lipids and other small molecules, which also 
self-assemble to form particulates that may be used to encapsulate drugs. One 
example of such a system is deoxycholic acid conjugated with HA, which results 
Figure 3. 
(A) Synthesis of 2′-succinyalted paclitaxel (PTX) and cystamine (ss) modified hyaluronic acid (HA)-
g-paclitaxel (PTX) [HA–ss–PTX] through two consecutive pathways. Initially, PTX was functionalized 
with succinic anhydrate to obtain an active free carboxylic acid group which was further grafted with HA 
in the presence of cystamine as a cross-linker using EDAC. HCl and NHS reaction chemistry mechanism.
[A(i&ii)] illustrate the schematic and TEM images of HA-PTX based self-assembled structure. [Ref. [26], 
adapted with permission from publishing authority]. (B) Schematic presentation of the synthesis of amide 
methyl 4 (aminomethyl) benzoate crosslinked with self-assembled HA-doxorubicin graft. (C) Synthesis of 
2, 7-succinyalted cisplatin [2, 7-Succ-Pt(IV)] followed by ethylene diamine (EDA) mediated conjugation 
with HA using EDAC. HCl and NHS reaction chemistry to form HA-EDA-Pt(IV) pro-drug. [C(i&ii)] 
AFM images of HA–EDA–Pt (IV) nanoconjugate at an optimal dilution ratio, indicating the formation 
of microspheres with an average diameter of 200 nm. [Ref. [31], adapted with permission from publishing 
authority].
Extracellular Matrix - Developments and Therapeutics
6
in the formation of micelles that may, in turn, be loaded with drug molecules 
(Figure 4(A)). In the specific study presented in this figure, Huo and colleagues 
showed that the average hydrodynamic size and colloidal stability in terms of ‘zeta 
potential’ of the resultant micelle was 120 nm and 36 mV, respectively. These par-
ticles were capable of releasing taxol (the drug here) into the cytoplasm of cancer 
cells, causing tumor apoptosis, with a minimum adverse effect on healthy cells 
[32]. In another study, cholesterol coupled HA was employed as the amphiphilic 
molecule that self-assembles into nanoparticles that encapsulate both the anti-
cancer drug Dox and magnetic nanoparticles (Figure 4(B)). This multifunctional 
delivery system exhibited high cytotoxicity and cellular uptake against several 
cancer cell lines such as HeLa, HepG2, and MCF7 [33].
Utilizing HA-molecule conjugated self-assembled nanovehicles for drug loading 
enables the development of combinatorial therapeutic approaches. As an example 
of such an approach, the photo-sensitizer, Ce6, has been coupled with HA to form a 
self-aggregated system that is capable of delivering therapeutic drugs. Such a system 
was used in a human colon xenograft and displayed a significant anti-tumor effect 
Figure 4. 
(A) Schematic illustration of cystamine (ss) cross-linked deoxycholic acid (DOCA) conjugated hyaluronic 
acid (HA) [HA-ss-DOCA conjugate] nanoparticles. (B) Schematic illustration of the synthesis of cholesterol-
conjugated HA (ch-HA) and the formation of DOX/SPION loaded ch-HA micelles. [Ref. [33], adapted with 
the permission from publishing authority]. (C) Schematic illustration of the preparation of HA-grafted 
micelles (HA-M) [Ref. [36], reproduced with permission from publishing authority]. (D) Preparation of  
HA/TN-CCLP and other liposomes. [Ref. [37], adapted with permission from publishing authority.
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in a mouse model [34, 35]. In the case of brain tumor therapy, the delivery of che-
motherapeutic agents is hindered by the sophisticated blood–brain barrier (BBB) 
[36], and such combinatorial therapeutics could be beneficial for hard-to-treat 
cancers such as glioblastoma multiforme (GBM). Combinatorial chemotherapy 
strategies based on lauroyl-gemcitabine, honokiol (HNK), and HA grafted micelle 
formulations (Figure 4(C)) were shown to significantly suppress GBM in an in vivo 
xenograft model [36]. Similarly, Liposomes composed of TAT-NBD (TN, a 22 amino 
acid cell-penetrating peptide) modified HA, encapsulating celecoxib (CXB) and 
curcumin (CUR) (HA/TN-CCLP) (Figure 4(D)) were reported to block nuclear 
factor-κB (NF-κB) and signal transducer and activator of transcription 3(STAT3) 
signaling pathways, potentially inhibiting tumor growth and metastasis by improv-
ing infiltration of inflammatory cells [37].
3.3 Gel formulations
One of the major advantages of using HA is its ability to be used in diverse 
forms. As HA is an extracellular matrix protein, it may also be used to form hydro-
gels by itself or in combination with other polysaccharides. Injectable polymeric 
hydrogels have made a significant contribution to active targeted delivery of 
chemotherapeutic agents as the 3-dimensional porous environment allows for pH or 
thermo-sensitive controlled intracellular release of cargo. A HA modified chitosan 
grafted poly-N-isopropylacrylamide hydrogel was reported to have the loading 
capacity of Dox/folic acid-g-graphene sheets with high killing efficacy against 
MCF7 breast cancer cells. An in vivo study also demonstrated delivery of anti-tumor 
agents using the same system [38].
Interferon α-2a (IFN α-2a) loaded HA–tyramine hydrogels have also been 
shown to have anti-tumor effects, while native IFN α-2a injection did not show 
any anti-cancer effects. This was due to the controlled release of IFN α-2a from the 
hydrogel network [39]. Such gels may also be developed as nano-formulations, as 
demonstrated by Jaya Kumar and colleagues who showed that a redox-sensitive Dox 
loaded chitin-cystamine-HA nanogel may be used to specifically kill CD44+ HT-29 
cells [40].
3.4 Graphene oxide (GO) based formulations
In the past couple of decades, carbonaceous compounds have gained significant 
attention in cancer therapy due to their large surface area and bio-sensing, bio-
imaging, cellular probing, and drug carrier abilities. Owing to its 2D structure, 
biocompatibility, and water-dispersion features, graphene oxide (GO) and its HA 
conjugate have been investigated as anti-cancer drug delivery platforms. Three 
specific examples are discussed here.
First is the development of HA and Arg-Gly-Asp (RGD) peptide coated gra-
phene oxide as a nano-carrier for Dox. Raman spectroscopic analysis revealed two 
strong peaks at 1350 cm−1 and 1550 cm−1 due to the presence of D and G bands in 
exfoliated graphene oxide, as shown in Figure 5(A), which was further confirmed 
by TEM. The nano-carrier was composed of a single transparent layer with a gauze-
like lid layer. It exhibited high Dox loading capacity and excellent cytotoxicity when 
tested on an ovarian cancer cell line, SKOV-3. It was also found to be biocompatible 
when tested on a healthy human cell line, HOSEpiC [41].
The second is the development of a redox-sensitive near-infrared (NIR) con-
trolled system consisting of both HA and GO. Yin et al. demonstrated (Figure 5(B)) 
that a Dox/HA-cystamine-GO nano-carrier displays selective targeting and glutathi-
one responsive release of Dox in the cytosol without any collateral damage to healthy 
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Figure 5. 
(A) Schematic illustration of the preparation and characterization of RBITC labeled Q-graphene (HA-Q-G-
RBITC)/DOX nanoparticles and HA-mediated endocytosis. (i) XPS analysis of Q-graphene (a), Q-graphene-
COOH (b), Sulf-Q-graphene (c), and PEG Q-graphene (d). (ii) TEM image of Q-graphene. (iii) cytotoxic 
effects of Q-G-RBITC/DOX, HA-Q-G-RBITC/DOX, and DOX against A549 cells with increasing DOX 
concentration. The error bar represents standard deviation (n = 5). (iv) CLSM images of A549 cells incubated 
with (A) HA-Q-G-RBITC, (B) HAQ-G-RBITC/DOX, or (C) Q-G-RBITC/DOX for 5 h. (D) MRC-5 
cells incubated with HA-Q-G-RBITC/DOX for 5 h. [Ref. [41], reproduced with permission from publishing 
authority]. (B) Synthesis of HSG-DOX nanosheets. (i) Raman absorption spectra of HCG, HSG, GO-COOH, 
and GO. (ii) In vitro DOX release from HSG-DOX after incubation with glutathione at 37°C. (iii) In vivo 
fluorescent imaging of MDA-MB-231 tumor-bearing nude mice at 4, 16, and 36 h after intravenous injection 
of Cy7-labeledHSG-DOX and HCG-DOX nanosheets with or without pre-injection of free HA at HSG/HCG 
dose of 5 mg/kg. (iv) tumor growth curves after intravenous injection of different formulations at a DOX dose 
of 5 mg/kg. **P < 0.01. [Ref. [12], reproduced with permission from publishing authority]. (C) Synthesis of 
dox loaded magnetite nanoparticles/GO-HA. Cytotoxicity induced by combination of drug treatment and 
hyperthermia. GO-HA-iron oxide particulates (i) without or (ii) with dox were cultured with MDA-MB-231 
cells and exposed to magnetic fields, and cell viability was measured. Cell viability measurements are 
normalized to control cultures of cells in the absence of particulates, drugs, and hyperthermia. Paired Student’s 
t-test was performed to compare hyperthermia treatment to their respective no-heat controls. **p < 0.01.  
[Ref. [43], adapted with permission from publishing authority].
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cells. As compared to free Dox, the NIR irradiated nanosystem exhibited enhanced 
cytotoxicity in a xenograft tumor model [12]. A similar cytotoxic effect was observed 
when HiLyte 647 loaded nano GO-HA was used to treat melanoma. Photo-thermal 
treatment resulted in the complete ablation of tumor tissue without any further 
tumorigenesis [42].
The third example is our own work on a formulation containing magnetic 
nanoparticle decorated GO-HA, which was evaluated for magnetothermal and 
CD44 (+) positive breast cancer targeted cancer therapy. A shown in Figure 5(C), 
the nanoplatform can be loaded with various types of chemotherapeutic agents 
such as Dox and Ptx. Furthermore, the study revealed that the nanoplatform had 
significant anti-tumor activity under magnetic hyperthermia in the MDA MB231 
cell line. These nanovehicles provide a versatile platform for next-generation cancer 
therapy [43].
3.5 Other carriers
Owing to their high stability, biocompatibility, and tunable porous architecture, 
mesoporous silica nanoparticles (MSNPs) have been used as multifunctional 
tumor-targeting nano-carriers. Dox loaded HA modified MSNPs have been 
developed and tested against HCT-116 cells, as shown in Figure 6(A). As part of 
the morphological analysis, TEM revealed spherical nanoparticles organized as a 
hexagonally packed mesoporous structure with a mean particle size of 70–100 nm. 
Surface modification of the MSNPs was confirmed by 13C NMR analysis. Strong 
absorption peaks at 43, 22, and 10 ppm and broad peaks at 70–180 ppm confirmed 
the presence of the methylene carbon in NH2-MSNPs and the anomeric carbon in 
HA, respectively. Compared to free Dox and Dox loaded MSNPs, Dox-HA-MSNPs 
exhibited a significantly greater anti-proliferative effect because of better CD44 
mediated uptake of HA modified nanoparticles at physiological pH [44].
A similar approach was used to fabricate mesoporous silica nanoparticles, 
post-functionalized with PEG-PDS-NH2 [poly(poly(ethyleneglycol) methacrylate-
co-pyridyldithioethyl methacrylate-co-2 aminoethylmethacrylate], followed by HA 
decoration for selective targeting. As shown in Figure 6(B), Dox loaded nanopar-
ticles demonstrated clathrin and macropinocytosis-mediated cellular uptake with 
the killing of CD44 positive HeLa cells [45].
Gold nanoparticles (AuNPs) in cancer therapy have dual functionality due to the 
presence of a bioactive surface, contrast ability, and photodynamic features. Kang 
et al. developed HA conjugated pheophorbide-A coated AuNPs (Figure 6(C)) that 
had excellent colloidal stability and photoactivity in the intracellular environment 
[46]. Electron microscopy analysis of the hybrid nanomaterial revealed spherical 
nanoparticles with a mean diameter of 70–80 nm, whereas native gold nanopar-
ticles had a mean diameter of 10–15 nm. The increase in size is attributed to the 
surface coating of the AuNPs. Active targeting was observed 48 h post-injection 
of PheoA-HA/AuNPs as indicated by bright fluorescence intensity at the tumor 
site rather than elsewhere, suggesting CD44 receptor-mediated accumulation of 
nanoparticles with minimum adverse effects on healthy tissues. In vivo study of 
administration of PheoA-HA/AuNPs revealed their excellent anti-tumor efficacy 
with 3-fold to 5-fold decrease in tumor size compared to free PheoA, saline, and 
AuNPs. In another study, Wang et al. synthesized {(Au0)100G5.NH2-FI-DOTA 
(Mn)-HA, where DOTA-1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic 
acid} NPs which facilitated selective internalization of dendrimers in tumor cells 
whose imaging capability is presented in Figure 6(D) [47].
Super-paramagnetic iron oxide nanoparticles have gained tremendous 
attention in targeted cancer therapy due to their diverse properties, including 
Extracellular Matrix - Developments and Therapeutics
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Figure 6. 
(A) Synthesis of different hyaluronic acid (HA) modified metal nano formulations for targeted cancer therapy. 
[A(i&ii)]. 13CNMR spectra of NH2-MSNs and HA-MSNs. [iii(a&b)]. TEM images of MSNs and (iv) 
HA-MSNs. (D) Cytotoxicity of free dox, dox-HA-MSNs, dox-MSNs, HA-MSNs and MSNs againstHCT-116 
cells at different concentrationsC1, C2andC3 (for details, see table v). [Ref. [44], adapted with permission 
from publishing authority]. (B) Schematic illustration of efficient mesoporous nanoparticle-mediated DDSs 
using noncovalent polymer gatekeepers and HA conjugation for targeting capability. (i) TEM images of 
HA-PMSNs, (ii) cumulative dox release profiles of 62 Mol% crosslinked PMSNs with (1 and 5 mM) and 
without GSH. (iii) cell viability analysis of HA-PMSNsCD44-positive in HeLa cells. [Ref. [45], adapted 
with permission from publishing authority]. (C) Schematic representation of the synthesis of {(Au0)100G5.
NH2-FI-DOTA (Mn)-HA} NPs. (i) TEM image of the {(Au0)100G5.NH2-FI-DOTA (Mn)-HA} NPs. The 
scale bar in each panel measures 20 nm. (ii) In vivo CT images of orthotopic liver tumors at different times 
after a 0.3-mL intravenous injection of a {(Au0)100G5.NH2-FI-DOTA (Mn)-HA} NP solution (0.3 mL 
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biocompatibility, enabling their use as a contrast agent for MRI and in magneto-
thermal therapy. Moreover, their tendency for aggregation in an aqueous medium 
is avoided by coating with active biopolymers and cancer-targeting agents. For 
example, HA modified and fluorescein isothiocyanate decorated iron nanoparticles 
may be utilized as an efficient probe for targeted MRI assisted cancer therapy, as 
shown in Figure 6(E) [48].
Another use of these particulates could be targeted brain tumor therapy, and 
a specific example is the development of HA-polyethylene glycol stabilized mag-
netite nanoparticle modified nano-sized liposomes. Dox loaded versions of these 
nanoparticles were shown to enhance drug release under induced hyperthermia 
(43°C). Confocal microscopy and flow cytometry analysis revealed CD44 targeted 
internalization of liposome nanoparticles in glioblastoma (U87 cells) tumor cells 
with a dual effect i.e. magneto-thermal and chemotherapeutic triggered the killing 
of tumor cells in vitro, suggesting their potential role as next-generation in vivo 
anti-cancer nano-vehicles [49].
4. Immunogenicity of HA-based nanoparticles
The extent of interaction between nanoparticles and serum proteins, i.e. the 
formation of the protein corona, is a key factor deciding the intravenous delivery 
efficiency of the nanoparticles. The protein corona may be modified using coatings 
that alter the surface properties of the nanoparticles. Almalik et al. showed that 
modifying chitosan NPs with HA avoided inflammatory protein adsorption com-
pared to nanoparticles not coated with HA [50]. Similarly, reactive oxygen species 
(ROS) production was suppressed when activated macrophages were treated with 
HA modified chitosan nanoparticles. The secretion of cytokines such as TNF-α 
and IL-1β were drastically reduced, indicating low immunogenicity of the HA-CS 
NPs without any collateral biological responses [51]. Zaki et al. also demonstrated 
that HA-chitosan NPs were taken up at a relatively slower rate compared to NPs not 
coated with HA. Moreover, the extent of internalization was two-fold lesser [52]. 
Further studies are required to verify that HA coatings decrease the immunogenic-
ity of particulates.
5. Conclusions
Research in the development of active cancer-targeting agents led to the dis-
covery of various cell surface molecules that control cellular function via different 
signaling pathways. CD44 is a cell surface protein that plays a significant role in 
tumorigenesis, metastasis, and proliferation of cancer cells. Several studies have 
demonstrated that the interaction of CD44 and HA, an extracellular component, 
in PBS, [Au] = 120 mM). (iii) In vivo MR images of orthotopic liver tumors at different times after an 
intravenous injection of 0.3 mL of a {(Au0)100G5.NH2-FI-DOTA (Mn)-HA} NP (300 μg Mn) solution in 
PBS. [Ref. [47], adapted the permission from publishing authority]. (D) Synthesis of HA-modified magnetite 
nanoparticles (HA-Fe3O4 NPs) (i) TEM micrographs of HA-Fe3O4 NPs. The viability of MIAPaCa-2 cells 
after treated with PBS, nHA-Fe3O4 NP and HA-Fe3O4 NPs at the different Fe concentrations for 24 h (ii) 
or 48 h (iii) at 37 oC by the CCK-8 assay (iv) In vivo transverse T2 MR images of tumors after intravenous 
injection of the nHA-Fe3O4 NP ((a) 7 days; (c) 14 days; (e) 21 days) and HAFe3O4 NPs ((b) 7 days; (d) 
14 days; (f) 21 days) ([Fe] 1 mg/mL, in 200 mL saline) at different time points post i.v.-injection. (v) In vivo 
biodistribution of hearts, livers, spleens, lungs, kidneys, and tumors 24 h post intravenous injection of the nHA-
Fe3O4 NP and HA-Fe3O4 NPs (600 mg Fe, in 0.3 mL PBS). (vi) The ability of MIAPaCa-2 cells to uptake 
PBS (a), nHA-Fe3O4 NP (b) and HA-Fe3O4 NPs (c) ([Fe] 50 mg/mL) 4 hours after treatment, MIAPaCa-2 
cells treated with PBS were used as control, scale bar ¼ 10 mm. [Ref. [48], adapted with permission from 
publishing authority].
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leads to the progression, growth, and metastasis of cancer cells via different sig-
naling pathways. Consequently, strategies have been developed to fabricate HA 
mediated tumor targeting nanoplatforms. Moreover, it has been reported that 
conjugation of HA with different nanoparticles increases the internalization of 
therapeutic molecules via enhanced permeability and retention or CD44 medi-
ated endocytosis with increased therapeutic efficacy both in vivo and in vitro. 
Particularly, various drug loaded targeting strategies have emerged, including 
redox, thermosensitive, and pH sensitive self-assembled HA-prodrug delivery and 
HA modified metallic and non-metallic nanovehicle-mediated delivery. In sum-
mary, HA-based nanoliposomes, micelles, and nano-carriers are promising thera-
peutic platforms for the delivery of multifunctional cargo in the context of active 
targeted cancer therapy, paving the way for next-generation clinical cancer therapy.
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